ÂÜÀòÂÒÂ×

Felix Moser is an accomplished leader in the field of synthetic cell technologies, currently serving as the CEO of Synlife since January 2017, where innovative biotherapeutic formulations for medical challenges, including alcohol poisoning, are developed. Prior experience includes a role as a Scientific Consultant at lululemon, focusing on strategic partnerships and advanced biomaterials, and as a Scientist at Scribio, contributing to virisome drug delivery research. Academic credentials feature a PhD in Biological Engineering from the Massachusetts Institute of Technology, complemented by dual MS degrees in Bioengineering from the University of California, Berkeley, and the University of California, San Francisco. An early career includes tenures as a Postdoctoral Associate at MIT, a Graduate Student at UC Berkeley, and a summer research assistant at the National Institutes of Health, highlighting a robust foundation in biomedical research and engineering.